In vivo experiments confirmed that inhibiting Gal-3 combined with gemcitabine reduces pancreatic cancer cell growth. (IMAGE)
Caption
(A) Schematic description of the drug combination experimental design in mice. (B) Images of the orthotopic xenograft model by 3D detection and tumor growth in the tail of the pancreas. (C) Mice with luciferase-labeled Panc-1 cells and HPSCs were treated with gemcitabine, and tumor growth was monitored via bioluminescence imaging. n = 6. (D) Quantification of the fluorescence intensity of the mice in each group. The blue arrow indicates the start day of drug treatment. (E) At the end of the in vivo xenograft study, the whole pancreas, including the transplanted tumors, was removed for analysis. Bar = 1 cm. (F) Body weights of mice were measured every 5 days. (G, H) Quantification of the tumor volume (G) and weight (H) in different groups of mice. (I) Immunohistochemical images show NOX1 and p-ERK expression in tumors from different groups. Bar = 200 μm “∗” indicates statistical significance. Gal-3, galectin-3; NOX1, NADPH oxidase 1; HPSCs, human pancreatic stellate cells; p-ERK, phosphorylated extracellular signal-regulated kinase.
Credit
Yaheng Wu, Guo An, Jia Tong, Wenlong Zhang, Zhihua Tian, Bin Dong, Xijuan Liu, Lin Zhao, Chunxian Ye, Jingtao Liu, Wei Zhao, Huachong Ma
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND